All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Brentuximab vedotin receives positive CHMP opinion in combination with CHP as treatment for adult patients with previously untreated sALCL
On March 31, 2020, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization for the anti-CD30 antibody–drug conjugate, brentuximab vedotin. The CHMP recommended its approval in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).1
The CHMP decision was based on positive data from the phase III ECHELON-2 trial (NCT01777152). The trial demonstrated favorable clinical activity of brentuximab vedotin plus CHP vs cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as first-line treatment in patients with CD30+ peripheral T-cell lymphoma (PTCL), which included the sALCL subtype. Treatment with brentuximab vedotin plus CHP improved progression-free survival by 29% compared to CHOP administration, with a comparable safety profile. 1
Read the Lymphoma Hub’s coverage of the ECHELON-2 trial here, and watch Ranjana Advani discuss it below.
ECHELON-2 trial: response by CD30 expression
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?